脱发作为 CGRP 单克隆抗体的新出现不良反应：病例系列、FAERS 评估和文献回顾。
Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review.
机构信息
Department of Biological Sciences, Florida International University, Miami, Florida, USA.
Department of Neurology, Division of Headache, University of Miami Miller School of Medicine, Miami, Florida, USA.
出版信息
Cephalalgia. 2023 Feb;43(2):3331024221143538. doi: 10.1177/03331024221143538.
BACKGROUND
Alopecia is associated with erenumab post-marketing, but no cases have been described.
METHODS
We describe two patients that reported temporary hair loss and review the FDA Adverse Event Reporting System (FAERS).
RESULTS
The first patient experienced alopecia within three months of starting erenumab, which did not improve with ongoing use or transition to fremanezumab. The second patient reported alopecia within two weeks of starting erenumab, which continued after transition to galcanezumab; months later, there was also recurrent hair loss within one month of starting fremanzeumab. According to FAERS (last accessed 18 August 2022), alopecia was reported most with erenumab (1158), followed by galcanezumab (554), fremanezumab (175), eptinezumab (23), rimegepant (26), ubrogepant (4), and atogepant (3).
CONCLUSION
Most events were reported in women and non-serious. The potential mechanism of alopecia with drugs targeting calcitonin gene-related peptide or its receptor possibly includes disruptions in the microvascular circulation and other homeostatic mechanisms.
背景
依那西普在上市后与脱发有关，但尚未有病例描述。
方法
我们描述了两名报告脱发的患者，并回顾了 FDA 不良事件报告系统（FAERS）。
结果
第一位患者在开始使用依那西普三个月内出现脱发，持续使用或改用佛美曲坦后未见改善。第二位患者在开始使用依那西普两周内报告脱发，改用加兰曲肽后仍持续脱发；几个月后，改用佛美曲坦一个月内也再次脱发。根据 FAERS（最后访问日期为 2022 年 8 月 18 日），脱发的报告最多的是依那西普（1158），其次是加兰曲肽（554）、佛美曲坦（175）、eptinezumab（23）、rimegepant（26）、ubrogepant（4）和 atogepant（3）。
结论
大多数事件报告发生在女性且为非严重事件。脱发与靶向降钙素基因相关肽或其受体的药物有关，其潜在机制可能包括微血管循环和其他体内平衡机制的破坏。
Zotero 插件